NCT01505751

Brief Summary

G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
69

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 27, 2011

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 9, 2012

Completed
23 days until next milestone

Study Start

First participant enrolled

February 1, 2012

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2015

Completed
Last Updated

September 7, 2016

Status Verified

July 1, 2015

Enrollment Period

3 years

First QC Date

December 27, 2011

Last Update Submit

September 4, 2016

Conditions

Cervical Cancer

Keywords

Outcome of cervical cancer

Outcome Measures

Primary Outcomes (1)

  • determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer

    From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months

Secondary Outcomes (1)

  • determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer

    From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months

Study Arms (1)

cervical cancer

Eligibility Criteria

Age20 Years - 99 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or chemotherapy) in Far Eastern Memorial Hospital

You may qualify if:

  • cases with cervical cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

Banqiao District, New Taipei, 22050, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

Residual pathology block after pathological exam

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief, Department of Obstetrics & Gynecology

Study Record Dates

First Submitted

December 27, 2011

First Posted

January 9, 2012

Study Start

February 1, 2012

Primary Completion

February 1, 2015

Study Completion

February 1, 2015

Last Updated

September 7, 2016

Record last verified: 2015-07

Locations

TW(1)